These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 29374234)

  • 1. Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies.
    Leclerc E; Combarel D; Uzunov M; Leblond V; Funck-Brentano C; Zahr N
    Sci Rep; 2018 Jan; 8(1):1681. PubMed ID: 29374234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifungal prophylaxis with posaconazole tablet and oral suspension in patients with haematologic malignancy: Therapeutic drug monitoring, efficacy and risk factors for the suboptimal level.
    Oh J; Kang CI; Kim SH; Huh K; Cho SY; Chung DR; Lee SY; Jung CW; Peck KR
    Mycoses; 2020 Jan; 63(1):89-94. PubMed ID: 31610064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections.
    Furuno JP; Tallman GB; Noble BN; Bubalo JS; Forrest GN; Lewis JS; Bienvenida AF; Holmes CA; Weber BR; McGregor JC
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections.
    Pham AN; Bubalo JS; Lewis JS
    Mycoses; 2016 Apr; 59(4):226-233. PubMed ID: 26742659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
    Cornely OA; Duarte RF; Haider S; Chandrasekar P; Helfgott D; Jiménez JL; Candoni A; Raad I; Laverdiere M; Langston A; Kartsonis N; Van Iersel M; Connelly N; Waskin H
    J Antimicrob Chemother; 2016 Mar; 71(3):718-26. PubMed ID: 26612870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posaconazole pharmacokinetics after administration of an intravenous solution, oral suspension, and delayed-release tablet to dogs.
    Kendall J; Papich MG
    Am J Vet Res; 2015 May; 76(5):454-9. PubMed ID: 25909378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posaconazole liquid vs tablet formulation in lung transplant recipients.
    Stelzer D; Weber A; Ihle F; Matthes S; Ceelen F; Zimmermann G; Kneidinger N; Schramm R; Winter H; Zoller M; Vogeser M; Behr J; Neurohr C
    Mycoses; 2018 Mar; 61(3):186-194. PubMed ID: 29110351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension.
    Durani U; Tosh PK; Barreto JN; Estes LL; Jannetto PJ; Tande AJ
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4914-8. PubMed ID: 26055378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.
    Döring M; Cabanillas Stanchi KM; Queudeville M; Feucht J; Blaeschke F; Schlegel P; Feuchtinger T; Lang P; Müller I; Handgretinger R; Heinz WJ
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1281-1292. PubMed ID: 28258343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies.
    Cumpston A; Caddell R; Shillingburg A; Lu X; Wen S; Hamadani M; Craig M; Kanate AS
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4424-8. PubMed ID: 25987632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole.
    Guarascio AJ; Slain D
    Pharmacotherapy; 2015 Feb; 35(2):208-19. PubMed ID: 25644669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics of Posaconazole Tablets and Monte Carlo Simulations To Determine whether All Patients Should Receive the Same Dose.
    Petitcollin A; Boglione-Kerrien C; Tron C; Nimubona S; Lalanne S; Lemaitre F; Bellissant E; Verdier MC
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.
    Liebenstein TK; Widmer KM; Fallon MJ
    J Oncol Pharm Pract; 2018 Dec; 24(8):599-603. PubMed ID: 28768441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies.
    Boglione-Kerrien C; Picard S; Tron C; Nimubona S; Gangneux JP; Lalanne S; Lemaitre F; Bellissant E; Verdier MC; Petitcollin A
    J Cancer Res Clin Oncol; 2018 Jan; 144(1):127-134. PubMed ID: 28932906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for subtherapeutic levels of posaconazole tablet.
    Tang LA; Marini BL; Benitez L; Nagel JL; Miceli M; Berglund C; Perissinotti AJ
    J Antimicrob Chemother; 2017 Oct; 72(10):2902-2905. PubMed ID: 29091205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of Posaconazole Oral Suspension in Children Dosed According to Body Surface Area.
    Vanstraelen K; Colita A; Bica AM; Mols R; Augustijns P; Peersman N; Vermeersch P; Annaert P; Spriet I
    Pediatr Infect Dis J; 2016 Feb; 35(2):183-8. PubMed ID: 26544987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of posaconazole oral suspension or delayed-released tablet salvage treatment for invasive fungal infection.
    Kim JH; Benefield RJ; Ditolla K
    Mycoses; 2016 Nov; 59(11):726-733. PubMed ID: 27392814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies.
    Cojutti PG; Candoni A; Lazzarotto D; Rabassi N; Fanin R; Hope W; Pea F
    Br J Clin Pharmacol; 2018 Nov; 84(11):2544-2550. PubMed ID: 29975796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients.
    Vanstraelen K; Prattes J; Maertens J; Lagrou K; Schoemans H; Peersman N; Vermeersch P; Theunissen K; Mols R; Augustijns P; Annaert P; Hoenigl M; Spriet I
    Eur J Clin Pharmacol; 2016 Aug; 72(8):953-63. PubMed ID: 27066958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.
    Krishna G; Ma L; Martinho M; O'Mara E
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4196-201. PubMed ID: 22615291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.